The EvergreenHealth Multiple Sclerosis Center is conducting a randomized, double-blind, placebo-controlled, cross-over trial to assess the safety, tolerability, and efficacy of suvorexant (Belsomra®) in treating insomnia in adults with multiple sclerosis (MS) and fatigue.
Who may be eligible to participate?
Patients 18-75 years of age with a confirmed diagnosis of Multiple Sclerosis and Insomnia Disorder. Patients must be on a stable regimen of disease modifying therapy with no MS exacerbations for 60 days prior to screening.
What does participation involve?
This study will assess whether suvorexant (Belsomra®) is more effective than placebo in treating insomnia and fatigue in people with MS. Enrolled patients will come to the study site for 4 visits (45-90 minutes each) during the study. Patients will also have 3 or more phone conversations with a study coordinator.
Theodore Brown, MD, MPH, EvergreenHealth MS Center